SCHEMBL2318657

SCHEMBL2318657

C=CC(=O)Nc1cccc(I)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 8/20 0.65
TRPV1 Q8NER1 1/20 0.50
F13A1 P00488 1/20 0.49
LMNA P02545 1/20 0.49
TGM1 P22735 1/20 0.49
TGM3 Q08188 1/20 0.49
JAK3 P52333 3/20 0.48
MAP2K7 O14733 2/20 0.48
EGFR P00533 1/20 0.48
AURKA O14965 1/20 0.48
LPAR1 Q92633 1/20 0.47
LPAR2 Q9HBW0 1/20 0.47
BTK Q06187 2/20 0.47
GRIN2D O15399 1/20 0.45
GRIN3B O60391 1/20 0.45
GRIN1 Q05586 1/20 0.45
GRIN2A Q12879 1/20 0.45
GRIN2B Q13224 1/20 0.45
GRIN2C Q14957 1/20 0.45
GRIN3A Q8TCU5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4103284 0.87 TGM2 (0.76) TGM2F13A1LMNATGM1TGM3
SCHEMBL31043513 0.81 TGM2 (0.53) TGM2F13A1LMNATGM1TGM3
SCHEMBL17397388 0.80 TGM2 (0.67) TGM2F13A1LMNATGM1TGM3
SCHEMBL29380510 0.80 TGM2 (0.67) TGM2F13A1LMNATGM1TGM3
SCHEMBL1119155 0.80 TGM2 (0.67) TGM2F13A1LMNATGM1TGM3
SCHEMBL8701998 0.79 SIGMAR1 (0.49) TGM2TRPV1LMNAGRIN2DGRIN3B
SCHEMBL9838285 0.79 LPAR2 (0.77) TRPV1LPAR1LPAR2
SCHEMBL9838293 0.79 LPAR2 (0.77) TRPV1LPAR1LPAR2
SCHEMBL7368786 0.79 CYP1A2 (0.64) TRPV1LPAR1LPAR2GRIN2DGRIN3B
SCHEMBL8572562 0.79 CYP1A2 (0.64) TRPV1LPAR1LPAR2GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4673482-A1 RADIOPAQUE CROSSLINKED ACRYLAMIDE COPOLYMERS AND USES THEREOF Boston Scientific Scimed Inc. (US) 2026-01-07 EP disclosed
WO-2024182584-A1 RADIOPAQUE CROSSLINKED ACRYLAMIDE COPOLYMERS AND USES THEREOF BOSTON SCIENTIFIC SCIMED, INC. (US) 2024-09-06 WO disclosed
US-20240293583-A1 RADIOPAQUE CROSSLINKED ACRYLAMIDE COPOLYMERS AND USES THEREOF BOSTON SCIENTIFIC SCIMED, INC. (US) 2024-09-05 US disclosed
WO-2024050825-A1 COMPOUNDS AS MLKL INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2024-03-14 WO disclosed
US-20220017484-A1 INHIBITOR OF BRUTON TYROSINE KINASE BEIJING RECIPROCAPHARMACEUTICALS CO., LTD. (CN) 2022-01-20 US disclosed
WO-2020108619-A1 MNK INHIBITOR 上海迪诺医药科技有限公司 2020-06-04 WO disclosed
WO-2016183094-A1 BICYCLIC COMPOUNDS KALYRA PHARMACEUTICALS, INC. (US) 2016-11-17 WO disclosed
EP-2349982-A1 ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION Congenia S.r.l. (IT) 2011-08-03 EP disclosed
WO-2010049768-A1 ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION CONGENIA SRL (IT) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017484-A1 INHIBITOR OF BRUTON TYROSINE KINASE BTK, LYN, SYK TGM2 1910/4885TRPV1 3686/4885F13A1 566/4885
US-20240293583-A1 RADIOPAQUE CROSSLINKED ACRYLAMIDE COPOLYMERS AND USES THEREOF RAD51, TSG101, BRCA1 TGM2 1994/4885TRPV1 4522/4885F13A1 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.